MedPage Today on MSN

FDA Signals Regulatory Flexibility With Accelerated Approval of Rare Disease Drug

Tividenofusp alfa is the first approved treatment for neurologic complications of Hunter s ...

Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session

AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session Across the COAST 1, COAST 2, and SHORE phase 3 studies, amlitelimab, dosed ...
Targeted Oncology

Estradiol Patch Matches Standard Hormone Therapy in Phase 3 Trial

Transdermal estradiol offers fewer hot flashes and lower fracture rates, but higher rates of gynecomastia, as it meets the ...

Maryland Fire Departments Awarded $520,000 for Cancer Screenings using 20/20 BioLabs’ OneTest ™ Multi-Cancer Early Detection Blood Test

State-Funded Screening Initiative Highlights Growing Public Sector Support for Innovative Cancer Detection Tools GAITHERSBURG, Md., March 27, ...
MedPage Today on MSN

Active Surveillance for DCIS Moves Closer to Standard Option but 'Not Quite There'

Large randomized trial makes case for non-inferiority versus surgery; smaller study falls ...
Asianet Newsable on MSN

Lung cancer warning signs: 6 early symptoms you must never ignore

Lung cancer begins when abnormal cells in the lungs grow uncontrollably. These vital organs help you breathe, but the disease remains the leading cause of cancer-related deaths worldwide, making early ...

In radon's ground zero, leaders have failed to protect Ohioans from deadly gas for decades

Radon is sickening thousands of Ohioans a year. A Dispatch investigation found the state could be doing more to protect those ...

Dear Doctor: I have an ugly, fatty tumor on my thigh; what can I do to get rid of it?

I was diagnosed with a large fatty tumor on my left thigh. It’s very ugly. What can I do to get rid of it? -- V.O.P. ANSWER: ...

Eli Lilly and Company: Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with ...

Taltz and Zepbound used together provided comprehensive improvements in disease activity and patient-reported outcomes compared to Taltz monotherapy in TOGETHER-PsA ...
The Malaysian Reserve

Phase 3b data presented at AAD Annual Meeting show Lilly’s Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and ...

Taltz and Zepbound used together provided comprehensive improvements in disease activity and patient-reported outcomes compared to Taltz monotherapy in ...

Sanofi: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session

AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session Across the COAST 1, COAST 2, and SHORE phase 3 studies, amlitelimab, dosed ...
The Malaysian Reserve

AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting

Data highlights efficacy and safety of risankizumab in psoriatic disease, including high impact areas in psoriasis and long-term treatment of psoriatic ...